A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations

Claudia Canino, YuYing Luo, Paola Marcato, Giovanni Blandino, Harvey I. Pass, Mario Cioce

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Here we studied the relevance and modulation of aldehyde dehydrogenase (ALDH) expression in malignant pleural mesothelioma (MPM) chemoresistant cell subpopulations (ALDHbright cells), which survive pemetrexed + cisplatin treatment in vitro and in vivo. Expression of the ALDH1A3 isoform was invariably enriched in purified ALDHbright cells from multiple MPM cell lines and accounted for the enzymatic activity of those cells. RNAi mediated downregulation of ALDH1A3 reduced the survival of the ALDHbright cells at steady state and, much more, after pemetrexed + cisplatin treatment. We demonstrated, for the first time, that a pSTAT3(tyr 705)-NFkB(p65) complex is required for the repression of DDIT3 mRNA and this ensures high levels of CEBPβ-dependent ALDH1A3 promoter activity. Inhibition of STAT3-NFkB activity allowed high levels of DDIT3 expression with increased formation of a DDIT3-CEBPβ complex. This reduced the occupancy of the ALDH1A3 promoter by CEBPβ thus largely reducing the ALDH1A3 expression. Consequently, survival of ALDHbright cells in pemetrexed + cisplatin-treated cultures was impaired, following increased apoptosis. We show that such a mechanism is relevant in vivo and underlies the action of butein, a dual STAT3-NFkB inhibitor capable of abating the chemoresistance of mesothelioma cells in vivo. The possible broad translational relevance of the described mechanism is discussed.

Original languageEnglish
Pages (from-to)12637-12653
Number of pages17
JournalOncotarget
Volume6
Issue number14
Publication statusPublished - 2015

Fingerprint

Pemetrexed
Cisplatin
Cell Survival
Aldehyde Dehydrogenase
Mesothelioma
RNA Interference
Protein Isoforms
Down-Regulation
Apoptosis
Cell Line
Messenger RNA
Malignant Mesothelioma

Keywords

  • ALDH
  • CEBPβ
  • DDIT3
  • NFkB
  • STAT3

ASJC Scopus subject areas

  • Oncology

Cite this

Canino, C., Luo, Y., Marcato, P., Blandino, G., Pass, H. I., & Cioce, M. (2015). A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget, 6(14), 12637-12653.

A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. / Canino, Claudia; Luo, YuYing; Marcato, Paola; Blandino, Giovanni; Pass, Harvey I.; Cioce, Mario.

In: Oncotarget, Vol. 6, No. 14, 2015, p. 12637-12653.

Research output: Contribution to journalArticle

Canino, C, Luo, Y, Marcato, P, Blandino, G, Pass, HI & Cioce, M 2015, 'A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations', Oncotarget, vol. 6, no. 14, pp. 12637-12653.
Canino, Claudia ; Luo, YuYing ; Marcato, Paola ; Blandino, Giovanni ; Pass, Harvey I. ; Cioce, Mario. / A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. In: Oncotarget. 2015 ; Vol. 6, No. 14. pp. 12637-12653.
@article{3ab89b783d17455ba8062b958e6a5b96,
title = "A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations",
abstract = "Here we studied the relevance and modulation of aldehyde dehydrogenase (ALDH) expression in malignant pleural mesothelioma (MPM) chemoresistant cell subpopulations (ALDHbright cells), which survive pemetrexed + cisplatin treatment in vitro and in vivo. Expression of the ALDH1A3 isoform was invariably enriched in purified ALDHbright cells from multiple MPM cell lines and accounted for the enzymatic activity of those cells. RNAi mediated downregulation of ALDH1A3 reduced the survival of the ALDHbright cells at steady state and, much more, after pemetrexed + cisplatin treatment. We demonstrated, for the first time, that a pSTAT3(tyr 705)-NFkB(p65) complex is required for the repression of DDIT3 mRNA and this ensures high levels of CEBPβ-dependent ALDH1A3 promoter activity. Inhibition of STAT3-NFkB activity allowed high levels of DDIT3 expression with increased formation of a DDIT3-CEBPβ complex. This reduced the occupancy of the ALDH1A3 promoter by CEBPβ thus largely reducing the ALDH1A3 expression. Consequently, survival of ALDHbright cells in pemetrexed + cisplatin-treated cultures was impaired, following increased apoptosis. We show that such a mechanism is relevant in vivo and underlies the action of butein, a dual STAT3-NFkB inhibitor capable of abating the chemoresistance of mesothelioma cells in vivo. The possible broad translational relevance of the described mechanism is discussed.",
keywords = "ALDH, CEBPβ, DDIT3, NFkB, STAT3",
author = "Claudia Canino and YuYing Luo and Paola Marcato and Giovanni Blandino and Pass, {Harvey I.} and Mario Cioce",
year = "2015",
language = "English",
volume = "6",
pages = "12637--12653",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "14",

}

TY - JOUR

T1 - A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations

AU - Canino, Claudia

AU - Luo, YuYing

AU - Marcato, Paola

AU - Blandino, Giovanni

AU - Pass, Harvey I.

AU - Cioce, Mario

PY - 2015

Y1 - 2015

N2 - Here we studied the relevance and modulation of aldehyde dehydrogenase (ALDH) expression in malignant pleural mesothelioma (MPM) chemoresistant cell subpopulations (ALDHbright cells), which survive pemetrexed + cisplatin treatment in vitro and in vivo. Expression of the ALDH1A3 isoform was invariably enriched in purified ALDHbright cells from multiple MPM cell lines and accounted for the enzymatic activity of those cells. RNAi mediated downregulation of ALDH1A3 reduced the survival of the ALDHbright cells at steady state and, much more, after pemetrexed + cisplatin treatment. We demonstrated, for the first time, that a pSTAT3(tyr 705)-NFkB(p65) complex is required for the repression of DDIT3 mRNA and this ensures high levels of CEBPβ-dependent ALDH1A3 promoter activity. Inhibition of STAT3-NFkB activity allowed high levels of DDIT3 expression with increased formation of a DDIT3-CEBPβ complex. This reduced the occupancy of the ALDH1A3 promoter by CEBPβ thus largely reducing the ALDH1A3 expression. Consequently, survival of ALDHbright cells in pemetrexed + cisplatin-treated cultures was impaired, following increased apoptosis. We show that such a mechanism is relevant in vivo and underlies the action of butein, a dual STAT3-NFkB inhibitor capable of abating the chemoresistance of mesothelioma cells in vivo. The possible broad translational relevance of the described mechanism is discussed.

AB - Here we studied the relevance and modulation of aldehyde dehydrogenase (ALDH) expression in malignant pleural mesothelioma (MPM) chemoresistant cell subpopulations (ALDHbright cells), which survive pemetrexed + cisplatin treatment in vitro and in vivo. Expression of the ALDH1A3 isoform was invariably enriched in purified ALDHbright cells from multiple MPM cell lines and accounted for the enzymatic activity of those cells. RNAi mediated downregulation of ALDH1A3 reduced the survival of the ALDHbright cells at steady state and, much more, after pemetrexed + cisplatin treatment. We demonstrated, for the first time, that a pSTAT3(tyr 705)-NFkB(p65) complex is required for the repression of DDIT3 mRNA and this ensures high levels of CEBPβ-dependent ALDH1A3 promoter activity. Inhibition of STAT3-NFkB activity allowed high levels of DDIT3 expression with increased formation of a DDIT3-CEBPβ complex. This reduced the occupancy of the ALDH1A3 promoter by CEBPβ thus largely reducing the ALDH1A3 expression. Consequently, survival of ALDHbright cells in pemetrexed + cisplatin-treated cultures was impaired, following increased apoptosis. We show that such a mechanism is relevant in vivo and underlies the action of butein, a dual STAT3-NFkB inhibitor capable of abating the chemoresistance of mesothelioma cells in vivo. The possible broad translational relevance of the described mechanism is discussed.

KW - ALDH

KW - CEBPβ

KW - DDIT3

KW - NFkB

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84930012600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930012600&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84930012600

VL - 6

SP - 12637

EP - 12653

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -